HPMA copolymer-cyclopamine conjugate treatment significantly decreased prostasphere forming capacity and percentage of CD133+ PCSC enriched population in PC3 and RC-92a/hTERT prostate cancer cells. The gene discussed is PROM1; the disease is Familial prostate cancer.